

QIBA Vol-CT Tech Ctte: General Business

Monday, March 7, 2011

11 AM CT

Call Summary

In attendance:

Andrew Buckler, MS (QIBA Program Director)
(Moderator)
P. David Mozley, MD (CT Co-chair)
Maria Athelougou, PhD
Hubert Beaumont
David A. Clunie, MBBS
Charles Fenimore, PhD
Paul Garrett, MD
David Gustafson, PhD
Philip Judy, PhD
Michael McNitt-Gray, PhD

James Mulshine, MD
Kevin O'Donnell
Nicholas Petrick, PhD
Yuanxin Rong, MD, MPH
Ying Tang, PhD

RSNA

Fiona Miller
Madeleine McCoy

Discussion Items:

1. Review of Active Projects

- a. Field Test of Advanced Lung Disease Protocol
 - o Protocol version 1.4.1 on web needs correction
 - o Reconstruction interval to be corrected (3)
 - o Dr. Mozley to complete corrections and send to Mr. Bucker or Joe Koudelik for posting to the Wiki
 - o Feedback needed from end users to address the following:
 - How well structure of document worked
 - Suggested changes
 - Specifics that were used and which were ignored
 - Dr. Mozley to request access to copy of actual document or executive summary of used by 6 core labs
- b. Small Pulmonary Mass Profile under development
- c. Groundwork on active projects
 - o 1B Group analysis for all lesions complete
 - Call to be scheduled to review inter reader variances
 - o 1C on track with imaging acquisition completed
 - Final design of reading study underway
 - o 3A establishing study design
 - Characterization of algorithm performance is the goal

2. Lung Cancer Screening

- o Lung cancer screening trial findings may have relevance to QIBA
- o Growth rate of suspicious masses identified by screening could be interpreted as biomarker for lung cancer
- o Consider whether QIBA could be good model for this process
 - Potential for secondary analysis of data from NLST and/or I-ELCAP
 - Possibility of using batch analysis tool being developed with NIST grant
 - Ability of longitudinal study to be concordant with profile/qualification
- o Need to determine appropriateness of lung cancer screening as a QIBA activity
 - Work scope and timeline
 - Parties involved/responsibility
 - How will professional societies be engaged?
 - Is screening protocol sound?
- o Need to determine what QIBA's involvement should be
 - Funding models
 - Feedback needs to be sought from Technical and Steering committees before decision is made

3. **Pharma Data Request Letter (deferred to next call)**
4. **RSNA Abstracts (deferred to next call): Abstract Deadline, March 31, 2011**

Next Steps:

- Mr Buckler to post corrected protocol version 1.4.1 to the WIKI
- VOL-CT April 21st meeting in Chicago to be confirmed
- Additional discussion on lung cancer screening, pharma data request letter, and RSNA abstracts to be included in subsequent general business calls.